DNA Synthesis Market Regional Analysis:
North America Market Forecast
North America industry is likely to hold largest revenue share of 37.1% by 2035. The strong presence of research organizations and biopharma companies is augmenting the demand for DNA synthesis technologies. The rising prevalence of genetic and chronic disorders and the quick adoption of personalized medications are also contributing to DNA synthesis solution sales growth.
In the U.S., the increasing investments by government and non-government organizations in genomics and biotechnology are pushing the sales of DNA synthesis solutions. The National Institutes of Health (NIH) is one of the major contributors to the genomic programs that contribute to DNA synthesis market growth in the U.S. For instance, in April 2024, the National Institutes of Health (NIH) awarded USD 27 million to establish a new network of genomics-enabled learning health systems in the country.
In Canada, the presence of advanced healthcare facilities and national healthcare platforms for genome sequencing and analysis such as Canadian Genomics Enterprise is significantly contributing to the demand for DNA synthesis solutions. The quick adoption of new and personalized diagnosis and treatment plans for genetic diseases also drives the sales of synthesized DNA solutions.
Europe Market Statistics
By 2035, Europe DNA synthesis market is projected to capture over 23.3% revenue share owing to the high activities in drug discovery and development. The advancements in biotechnology and life science sectors are generating lucrative opportunities for DNA synthesis solution producers in the region.
In the U.K., well-known universities including Oxford and Cambridge constantly collaborate with biotech firms for research in genomics, drug discovery, and synthetic biotechnology, which contributes to DNA synthesis technologies. For instance, in October 2023, Evonetix announced that it successfully installed its first DNA synthesis development platform at the Imperial College London to optimize research in gene synthesis. Such strategic moves between institutions and industry giants are positively influencing the overall DNA synthesis market growth.
The swift integration of precision medicines into clinical practices, which relies highly on custom DNA synthesis is uplifting Germany’s market position in Europe. The genomDE strategy of the country that aims to enhance the adoption of genomic medicines is fueling the use of DNA synthesis solutions in drug development and gene therapies.
